PDF
ePub
Citation
Print
Abstract
Asthma is the most common chronic illness to affect children and is a major cause of morbidity in adults, affecting 4~17% of children and 7.3~10.1% of adults, which translates to approximately 300 million people globally. This article reviews recently published data over the past 1~2 years on asthma, and covers the 3 aspects of current advancement for the diagnosis of severe asthma, including the controversy to long-acting bronchodilator treatment for treatment of asthma, and the role of long-acting anticholinergics treatment in asthma patients.
Figures and Tables
References
1. World Health Organization (WHO). Bronchial asthma. World Health Organization Fact Sheet No. 307. 2008. Geneva, Switzerland: WHO.
2. Osborne M, Deffebach M. The epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. Ann Allergy Asthma Immunol. 2004. 92:3–4.
3. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma. Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004. 92:32–39.
4. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE. TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007. 62:126–133.
5. Global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma (GINA). 2006. cited 2011 Aug 10. GINA;Available from: http://www.ginasthma.org/.
6. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007. 119:405–413.
7. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003. 22:470–477.
8. Wenzel SE, Busse WW. National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol. 2007. 119:14–21.
9. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009. 180:59–99.
10. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010. 126:926–938.
11. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol. 2007. 119:1337–1348.
12. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011. 05. 27. [Epub]. Available from: http://dx.doi.org/10.1136/thx.2010.153643.
13. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004. 170:836–844.
14. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997. 337:1405–1411.
15. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006. 129:15–26.
16. Bailey W, Castro M, Matz J, White M, Dransfield M, Yancey S, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin. 2008. 24:1669–1682.
17. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010. 362:1169–1171.
18. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values. N Engl J Med. 2009. 360:1592–1595.
19. Riley K, Jefferson E. FDA announces new safety controls for long-acting beta agonists, medications used to treat asthma [Internet]. 2010. cited 2011 Aug 10. Silver Spring, MD: Food and Drug Administration;Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm.
20. National Heart, Lung, and Blood Institute (NHLBI). National asthma education and prevention program. Expert panel report 3: guidelines for the diagnois and management of asthma. 2007. Bethesda, MD: NHLBI.
21. Nelson H, Bonuccelli C, Radner F, Ottosson A, Carroll KJ, Andersson TL, et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol. 2010. 125:390–396.
22. de Vries F, Setakis E, Zhang B, van Staa TP. Long-acting β2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J. 2010. 36:494–502.
23. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med. 2009. 360:1671–1672.
24. National Institute for Health and Clinical Excellence (NICE). Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. NICE technology appraisal guidance 138. 2008. London, UK: NICE.
25. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev. 2004. (3):CD003269.
26. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005. 60:740–746.
27. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006. 533:36–39.
28. Ahmad Z, Singh SK. Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker sthmatics. J Asthma. 2010. 47:340–343.
29. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002. 19:217–224.
30. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003. 124:1743–1748.
31. Terzano C, Petroianni A, Ricci A, D'Antoni L, Allegra L. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci. 2004. 8:259–264.
32. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008. 102:50–56.
33. Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med. 2005. 171:1096–1102.
34. Ohta S, Oda N, Yokoe T, Tanaka A, Yamamoto Y, Watanabe Y, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010. 40:1266–1275.
35. Iwamoto H, Yokoyama A, Shiota N, Shoda H, Haruta Y, Hattori N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J. 2008. 31:1379–1380.
36. Kapoor AS, Olsen SR, O'Hara C, Puttagunta L, Vethanayagam D. The efficacy of tiotropium as a steroid-sparing agent in severe asthma. Can Respir J. 2009. 16:99–101.
37. Park HW, Yang MS, Park CS, Kim TB, Moon HB, Min KU, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009. 64:778–783.
38. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010. 363:1715–1726.
XML Download